ARC01 / China Grand Pharma - LARVOL DELTA

An Open, Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of ARC01 Injection for the Treatment of Patients with HPV16-Positive Advanced Unresectable or Recurrent/Metastatic Solid Tumors (ChiCTR) - P1 | N=17 | Recruiting | Sponsor: Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o | -> Recruiting | N=11 ➔ 17

Enrollment change • Enrollment open • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Vaginal Cancer

An Open, Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of ARC01 Injection for the Treatment of Patients with HPV16-Positive Advanced Unresectable or Recurrent/Metastatic Solid Tumors (ChiCTR) - P1 | N=11 | Sponsor: Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o

New P1 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Vaginal Cancer